Riskpilot← Back to searchSign inGet full accessAvepharm AB
ABBankruptOrg 5592861362Other specialised construction activities n.e.c. · NACE 4399Est. 20202 employees
Revenue 2022
SEK 2,4M
EBITDA margin
12.6%
Equity ratio
68.7%
Financial strength
Net profit 2022
SEK 237K
2 employees
| Revenue | SEK 2,4M | — |
| EBITDA | SEK 299K | — |
| Net profit | SEK 237K | — |
| Total assets | SEK 382K | — |
| Equity | SEK 262K | — |
| Employees | 2 | — |
Legal name
Avepharm AB
Org number
5592861362
Legal form
Aktiebolag
NACE code
4399 · Other specialised construction activities n.e.c.
Founded
27 november 2020
Share capital
SEK 25 000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Uppgift om firmateckning saknas Registrerad styrelse saknas. Då minst halva antalet styrelseledamöter och den verkställande direktören ska vara bosatta inom EES uppfyller företaget inte kravet på bosättning.
Company purpose
Bolaget skall direkt eller indirekt tillhandahålla & bedriva handel med receptfria kosmetika produkter samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 |
|---|---|---|
| Revenue | 0 | 2 365 |
| Staff expenses | −0 | −946 |
| EBITDA | — | 299 |
| Depreciation & amort. | — | — |
| EBIT | 0 | 299 |
| Net financials | — | — |
| Profit before tax | 0 | 299 |
| Tax | — | −62 |
| Net profit | 0 | 237 |
| Item | 2021 | 2022 |
|---|---|---|
| Total assets | 0 | 382 |
| Equity | 0 | 262 |
| Long-term debt | — | — |
| Short-term debt | 0 | 120 |
| Total debt | — | 120 |
EBITDA margin
12.6%
This company
15.8%
Market median
-20% vs market
20212022
Equity ratio
68.7%
This company
38.2%
Market median
+80% vs market
20212022
Return on equity
90.5%
This company
18.4%
Market median
+392% vs market
20212022
Net profit margin
10.0%
This company
8.1%
Market median
+23% vs market
20212022
Asset turnover
6.19×
This company
1.12×
Market median
+453% vs market
20212022
Debt / equity
0.46×
This company
0.62×
Market median
+26% vs market
20212022
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ME Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (2) | ||
SB Chief Executive Officer | Chief Executive Officer | 2022 – 2022 |
SA Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2024 | |
| Deputy Board Member | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Avepharm AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sara Benmakhlouf | Chief Executive Officer | 0 companies |
| Sigge Agnar Kolbjörn Skog | Chief Executive Officer | 0 companies |
| Mhamad Eyad El Tahan El Zaleq | Chief Executive Officer | 0 companies |
| Waldman Sturske Fritjof Skog | Deputy Board Member | 0 companies |
| Mohammad Shalabe | Deputy Board Member | 0 companies |
| David Benzén | Deputy Board Member | 0 companies |